SPYRE THERAPEUTICS, INC. Derivative, Gain (Loss) on Derivative, Net
SPYRE THERAPEUTICS, INC. (SYRE) reported Derivative, Gain (Loss) on Derivative, Net of -$1.44 million for the 12-month period ending 2014-12-31, per its 10-K filed 2017-03-23.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeGainLossOnDerivativeNet · last filed 2017-03-23
- SPYRE THERAPEUTICS, INC. derivative, gain (loss) on derivative, net for fiscal 2014 was -$1.44M.
| Period end | Derivative, Gain (Loss) on Derivative, Net 12 month |
|---|---|
| 2014-12-31 | -$1.44M 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |